Abstract
Compliance Aids have gained widespread use to assist patients in managing their medicines, with a view to addressing the issue of adherence. However, although patient outcomes may have been improved through better use of compliance aids, it has been highlighted that there are limited data on the stability of medicines, when removed from the original container and repackaged in a compliance aid. Exposure of medicines to heat, light, moisture and air (oxygen) may impact on both their chemical and physical stability, resulting in the potential for quality of the medicine and thus the safety for the patient being compromised. It is also uncertain whether the compliance aid can provide the same protection from these environmental conditions as the manufacturer’s packaging, even though the time frame for repackaging is only 28 days. This paper presents a comprehensive review and detailed discussion of the available literature on the stability implications of repackaging medicines into compliance aids. The importance of repackaging is thus highlighted by its ability to impact on therapeutic outcomes for patients.
Keywords: Dose Administration Aids, quality, repackaging, safety, stability, storage.
Current Drug Safety
Title:Evidence of Stability of Medicines Repackaged in Compliance Aids: A Review
Volume: 11 Issue: 1
Author(s): Alison Haywood and Beverley D. Glass
Affiliation:
Keywords: Dose Administration Aids, quality, repackaging, safety, stability, storage.
Abstract: Compliance Aids have gained widespread use to assist patients in managing their medicines, with a view to addressing the issue of adherence. However, although patient outcomes may have been improved through better use of compliance aids, it has been highlighted that there are limited data on the stability of medicines, when removed from the original container and repackaged in a compliance aid. Exposure of medicines to heat, light, moisture and air (oxygen) may impact on both their chemical and physical stability, resulting in the potential for quality of the medicine and thus the safety for the patient being compromised. It is also uncertain whether the compliance aid can provide the same protection from these environmental conditions as the manufacturer’s packaging, even though the time frame for repackaging is only 28 days. This paper presents a comprehensive review and detailed discussion of the available literature on the stability implications of repackaging medicines into compliance aids. The importance of repackaging is thus highlighted by its ability to impact on therapeutic outcomes for patients.
Export Options
About this article
Cite this article as:
Haywood Alison and Glass D. Beverley, Evidence of Stability of Medicines Repackaged in Compliance Aids: A Review, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886310666150928104931
DOI https://dx.doi.org/10.2174/1574886310666150928104931 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Perinatal Management of Fetal Tumors
Current Pediatric Reviews Is Age of 80 Years a Threshold for Carotid Revascularization?
Current Cardiology Reviews Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair
CNS & Neurological Disorders - Drug Targets Sex-Gender Differences in Diabetes Vascular Complications and Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets Type 2 Diabetes As An Inflammatory Cardiovascular Disorder
Current Molecular Medicine Maternal Sepsis 2010: Early Recognition and Aggressive Treatment with Early Goal Directed Therapy can Improve Maternal Outcomes
Current Women`s Health Reviews Current Updates on Therapeutic Advances in the Management of Cardiovascular Diseases
Current Pharmaceutical Design Echinoderms: Potential Model Systems for Studies on Muscle Regeneration
Current Pharmaceutical Design Twenty Years of Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy
Current Cardiology Reviews PPAR- γ Agonist in Treatment of Diabetes: Cardiovascular Safety Considerations
Cardiovascular & Hematological Agents in Medicinal Chemistry Mechanisms of Endothelial Dysfunction: Clinical Significance and Preventive Non-Pharmacological Therapeutic Strategies
Current Pharmaceutical Design Cardiovascular Disease Burden and Risk Factors Before and After Kidney Transplant
Cardiovascular & Hematological Disorders-Drug Targets The Cardioprotective Peptide, Urocortin, Activates Cardiac KATP Channels in Adult Rat.
Protein & Peptide Letters Remodeling of the Myocardium and Potential Targets in the Collagen Degradation and Synthesis Pathways
Current Drug Targets - Cardiovascular & Hematological Disorders Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Nanotechnology Based Diagnostic and Therapeutic Strategies for Neuroscience with Special Emphasis on Ischemic Stroke
Current Medicinal Chemistry Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Current Vascular Pharmacology Current Concepts and Controversies in the Use of Antenatal Corticosteroid Therapy for Prevention of Neonatal Morbidities
Current Women`s Health Reviews Proteinase-Activated Receptor 2 (PAR2): A Challenging New Target for Treatment of Vascular Diseases
Current Pharmaceutical Design